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Warfarin is a drug widely used for oral anti-
coagulation in patients with atrial fibrillation, 
venous thromboembolism or a prosthetic heart 
valve to reduce the risk of thromboembolic 
events [1]. The optimal warfarin dose is assessed 
by measuring the international normalized ratio 
(INR), which should be kept within a narrow 
range, since the risk of thromboembolic events 
decreases with an increasing INR, while the risk 
of bleeding events increases. A large inter- and 
intra-patient variability in warfarin dose require-
ment makes frequent INR monitoring neces-
sary. The required dosage is influenced by several 
factors, such as gender, age, diet, concomitant 
medication and genetic factors.
Polymorphisms in both the CYP2C9 gene, 
encoding for the main metabolizing enzyme, 
cytochrome P450 2C9 (CYP2C9), and the 
VKORC1 gene, encoding the target enzyme vita-
min K epoxide reductase multiprotein complex 
1, explain approximately a third of the varia-
tion in warfarin dose requirement. Information 
regarding the genotype of a patient can there-
fore be used to predict the warfarin maintenance 
dose. Although the ability of genotype-guided 
dosing to improve the safety and efficacy of war-
farin treatment has been investigated in a few 
small randomized controlled trials, there is still 
no clear evidence about the effectiveness of this 
dosing strategy [2].
The economic impact of genotyping patients 
prior to warfarin use is also not clear. Results 
from cost–effectiveness analyses of warfarin 
pharmacogenetics (using genetic information 
to determine the required dose) do not all point 
in the same direction [3–5]. In one of these studies 
genotyping appeared to be the dominant strat-
egy, meaning that genotyping was more effec-
tive and less costly than not genotyping [4]. By 
contrast, other studies found that the gain in 
effectiveness was coupled with higher costs [3,5]. 
In most studies the effect of genotyping was 
based directly on its observed or assumed impact 
on the risk of bleeding and thromboembolic 
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events, although the studies performed to date have not been 
large enough to detect reductions of adverse events. Using the 
association between the level of INR with the risk of bleeding 
and thromboembolic events, Meckley et al. developed a policy 
model to evaluate the clinical and economic consequences of 
pharmacogenetic-guided warfarin dosing, based on the effect of 
genotyping on INR levels [1].
Summary of methods & results
In their study Meckley et al. developed a decision analytic Markov 
model to perform an economic evaluation comparing genotype-
guided dosing with standard anticoagulation care using a life-
time horizon [1]. The base-case scenario focused on 65-year-old 
patients with atrial fibrillation who were initiated on long-term 
treatment with warfarin. Patients were stratified by genotype 
into three different groups: the first group consisted of CYP2C9 
wild-type/VKORC1 wild-type patients, the second of CYP2C9 
wild-type/VKORC1 variant patients, and in the last group were 
the CYP2C9 variants. This last group was not stratified by 
VKORC1 genotype for group size reasons. All patients entered 
the Markov model in a healthy (‘well’) state and could move 
from this state to the states ‘clot’, ‘bleed’, ‘sequelae’ or ‘death’ in 
monthly cycles. The probabilities to experience a major bleeding 
or thromboembolic event were based on the time spent within, 
above or below therapeutic INR range. The time patients spent 
within, above and below therapeutic INR range was based on data 
from the COUMAGEN trial [6]. This trial provided data on the 
difference in time spent in therapeutic INR range between the 
genotype-guided dosing group and the standard dosing group, 
but the authors reanalyzed the COUMAGEN data in order to 
obtain additional information regarding the time spent above or 
below this range. The differences in time spent within the differ-
ent INR ranges between the two dosing strategies were used in the 
model for the first month and reduced to zero in the sixth month 
of therapy. An increased bleeding risk of 2.26, independent of the 
effect of INR, was assumed from a meta-analysis for the CYP2C9 
variant patients, which was subjected to sensitivity ana lysis [7]. 
Utility (or quality-of-life) scores for the different health states 
were used to calculate the difference in quality-adjusted life-years 
(QALYs) between the standard and the genotype-guided dosing 
group. Genotyping itself was assumed to have no effect on the 
quality of life of the patient. The difference in costs between 
the two strategies was calculated and included only direct medi-
cal costs, since the authors applied a third party payer perspec-
tive. One-way sensitivity analyses were performed for all input 
parameters over prespecified ranges and several scenario analyses 
were conducted. The chance that the incremental cost–effective-
ness ratio (ICER) would fall below a certain willingness-to-pay 
threshold (e.g., US$50,000 per QALY gained) was calculated in 
a probabilistic sensitivity analysis using Monte Carlo simulations.
Meckley et al. found that pharmacogenetics could reduce the 
time spent above therapeutic INR range in the CYP2C9 variant 
group by 15%, and the time spent below therapeutic range in the 
CYP2C9 wild-type/VKORC1 wild-type group by 8% [1]. In the 
third group (CYP2C9 wild-type/VKORC1 variants) there were 
no differences in time spent above or below therapeutic INR 
range between the two dosing strategies. In the base case ana lysis 
the incidence of bleedings was reduced by 0.17%, the incidence 
of thromboembolic events increased by 0.03% and incidence of 
death reduced by 0.13% in the pharmacogenetic-guided dosing 
group. These differences resulted in a QALY increase of 0.0027. 
As genotyping also led to an overall cost increase of US$162, 
the ICER was US$60,725 per QALY gained. When looking at 
the ICERs in the different genotype groups, pharmacogenetic-
guided dosing was most cost effective in the group consisting of 
VKORC1 and CYP2C9 wild-type patients. In this group there 
was a decrease in the risk of bleedings, thromboembolic events 
and deaths. The ICER for this group was US$13,500 per QALY 
gained. For the patients with CYP2C9 variant alleles genotype-
guided dosing was dominated by the standard dosing strategy, 
meaning that genotyping resulted in a decrease in QALYs and an 
increase in costs. This result arose because of an increase in the 
frequency of thromboembolic events in this group.
The uncertainty around the cost of a pharmacogenetic test, as 
investigated in the one-way sensitivity ana lysis, caused the largest 
part of the uncertainty around the cost–effectiveness ratio. In one 
of the scenario analyses, data from Caraco et al. were used instead 
of data from the COUMAGEN trial [8]. In this scenario, the 
genotyping strategy was the dominant strategy. Genotyping was 
also the dominant strategy when it was assumed that genotyping 
reduced the bleeding risk in CYP2C9 variant patients further. 
The probabilistic sensitivity ana lysis revealed that there was a 15% 
chance that the pharmacogenetic-guided dosing was the dominant 
strategy. In addition, it was estimated that there was a 46% chance 
that the true ICER was below US$50,000 per QALY gained and 
a 67% chance that it was below US$100,000 per QALY gained.
Discussion
This study suggested that pharmacogenetic-guided dosing of war-
farin could improve the health of patients initiating warfarin while 
also increasing healthcare costs compared with a standard dosing 
regimen. The probability that genotyping would cost less than 
US$50,000 per QALY gained was estimated to be almost 50%. 
However, owing to uncertainty regarding the values of several 
input parameters, Meckley et al. found that the possible impact of 
genotyping ranged from a possibility that genotype-guided dosing 
is the dominant strategy to a possibility that it is less effective and 
more costly than a standard dosing regimen [1]. This wide range 
of possible realities is mainly due to uncertainty regarding the 
effectiveness of pharmacogenetic-guided dosing on the risk of 
serious adverse events or therapeutic failure of warfarin therapy.
Patients with a variant genotype have a higher risk of bleed-
ings due to warfarin therapy, because of a lower dose require-
ment. A genotype-guided dosing strategy might reduce this risk 
when patients with a variant genotype receive a lower dose. It is, 
therefore, remarkable that genotyping appeared to be less cost 
effective in patients with a variant genotype. This was explained 
by the increase in the number of thromboembolic events in this 
group, which might indicate that the dosages for these patients 
were overadjusted.
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Since the clinical trials performed to date provide no direct evi-
dence regarding the influence of genotyping on the incidence of 
adverse events or therapeutic failure, these authors used the time 
within, above and below therapeutic INR range as a surrogate for 
these clinical end points. This method has been used in two other 
studies investigating the cost–effectiveness of pharmacogenetic-
guided dosing of warfarin [5,9]. In the study of Patrick et al., data 
from the COUMAGEN trial [6] together with data from Caraco 
et al. [8] were used to calculate the effect of genotyping on the 
time spent within therapeutic INR range [9]. In a probabilistic 
sensitivity ana lysis Patrick et al. found a chance of 42% that 
genotyping would be cost effective given a willingness to pay of 
$50,000 per QALY [9], which is quite similar to the 46% in the 
study of Meckley et al. [1]. In the study of You et al. this chance 
was 38% [5] and the base case results were also less optimistic 
than in the Meckley et al. study [1], since they reported an ICER 
of $347,059 per QALY gained. In the study by You et al. lower 
baseline adverse event rates were used and the effect of geno typing 
was not stratified by genotype as in the current study. In the 
probabilistic sensitivity ana lysis by Meckley et al. the costs of the 
genetic test are also varied [1]. It would have been more useful to 
vary this parameter in a scenario ana lysis, because at the moment 
of decision-making the prices will be known already.
The development of this model using INR as a surrogate end 
point for bleedings and thromboembolic events seems very useful, 
as there is not enough evidence about the effect of genotyping on 
the adverse event rate. However, the uncertainty around the results 
of this study are still too large to allow any recommendations 
regarding the implementation of pharmacogenetics in treatment 
with warfarin. This uncertainty is mainly caused by the fact that 
there is not sufficient evidence regarding the effect of genotyping 
on INR ranges either, because this has only been investigated in 
a few small clinical trials. For some input parameters, such as the 
effect of genotyping on INR after the first month of therapy, the 
authors needed to make assumptions, because there is no evidence 
yet available on these parameters. Therefore, it is necessary to delay 
any recommendations regarding genotyping until more data from 
large clinical trials become available.
Expert commentary & five-year view
Pharmacogenetic-guided dosing of warfarin and other coumarin 
derivatives seems to be a promising new method to improve the 
safety and efficacy of oral anticoagulant therapy. Currently, the 
response to warfarin treatment is evaluated by INR measure-
ment after the first few days of therapy. The prescribed dose 
can then be adapted to the patient’s needs, so the patient will 
receive a more individualized dose after this first INR measure-
ment. However, in the first few days of therapy, no informa-
tion on the patient’s response is available, so all patients receive 
the same loading dose. If patients were to be genotyped before 
they started taking warfarin, the loading dose for the first few 
days could already be personalized. However, this would only 
be possible if the genotype results are available before warfarin 
initiation. Therefore, it is desirable to have a fast, reproducible 
and accurate method to genotype; for this purpose, point-of-care 
testing might be useful.
Meckley et al. have shown that pharmacogenetic-guided dosing 
could improve health at higher healthcare costs compared with 
standard care, but there is not enough information available yet 
on the effectiveness of this genotype-guided dosing method [1]. 
Moreover, as the study of You et al. [5] demonstrates, a low adverse 
event rate with warfarin therapy will make genotyping less cost 
effective. As a consequence, the cost–effectiveness of pharmaco-
genetic-guided warfarin dosing will differ between countries and 
will be particularly favorable in settings where warfarin therapy is 
complicated by a relatively high rate of bleedings and thrombo-
embolic events. The upcoming use of direct thrombin inhibitors 
might also reduce the value of genotype-guided warfarin dosing 
in the future to some extent. 
It is not yet fully known how to use the genetic information 
to adjust the prescribed warfarin dose. In the study of Meckley 
et al. it seemed that patients with a variant genotype were under-
dosed in the pharmacogenetic-guided dosing strategy [1]. Dosing 
algorithms, such as the dosing algorithm developed by the 
International Warfain Pharmacogenetics Consortium [10], there-
fore need to be developed and tested widely to find the optimal 
way of adjusting the dose of warfarin or other coumarin deriva-
tives according to the genetic information. It is also not yet clear 
whether the genetic information has any value for determining 
the right dose after the first few days of therapy, when the dose is 
also adjusted according to the INR values of the patients.
Within a few years, more data on this subject will become 
available, as several large clinical trials investigating the effective-
ness of pharmacogenetic-guided dosing algorithms in treatment 
with warfarin and other coumarin derivatives are now under-
way [11,101]. Since the primary outcome of these studies is time 
within therapeutic INR range, a model like the one presented 
in this study of Meckley et al. [1] would be very useful to assess 
not only the effectiveness but also the cost–effectiveness of a 
pharmacogenetic-guided dosing strategy.
Key issues
• Polymorphisms in the CYP2C9 and VKORC1 genes can explain a large part of the variation in dose requirement of warfarin.
• Pharmacogenetic-guided dosing might improve the safety and efficacy of warfarin treatment, because sub- or supra-therapeutic 
dosages put patients at increased risk of thromboembolic events or bleedings.
• Genotype-guided dosing has been shown to improve health, but also increase healthcare costs.
• A large uncertainty remains around the effectiveness of genotyping patients prior to warfarin treatment, as well as around the 
economic consequences of this strategy.
• Data from large clinical trials are necessary to reduce this uncertainty.
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